KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )
Tweet Send to a Friend
KeyBanc analyst Scott Schoenhaus reiterated an Overweight rating and $12.00 price target on Recursion Pharmaceuticals (NASDAQ: RXRX).The analyst commented, "Before ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
